Good year, bad year? Two biotech CEOs hit pay dirt in 2018 as com­pen­sa­tion pack­ages swell

By any ac­count­ing mea­sure, John Oyler had a big year last year, steer­ing BeiGene to a mon­ster $903 mil­lion Hong Kong IPO, then watch­ing the stock lan­guish as the Chi­na-based biotech put its PD-1 on a track to reg­u­la­tors. But what­ev­er short­com­ings may have been in the mix at BeiGene, they didn’t pre­vent the CEO from scor­ing one of the rich­est com­pen­sa­tion pack­ages in bio­phar­ma.

In a re­cent fil­ing with the SEC BeiGene $BGNE re­vealed that the com­pa­ny founder made off with a com­pen­sa­tion deal worth $27.9 mil­lion, a big step up from the $10.3 mil­lion he snagged in 2017 and the rel­a­tive­ly mod­est $4.6 mil­lion he got for 2016 — the year BeiGene’s first IPO hit Nas­daq. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.